Global law firm Goodwin today announced that Scott Bluni joined the Life Sciences practice as a partner, resident in the Boston office. Bluni is joined by a team including counsel Matt Fagan and Kevin Canning, senior attorney Martin Miller, and five intellectual property operations professionals.
“Advancements in robotics, machine learning, and artificial intelligence continue to fuel innovation and investment among our medtech clients,” said Mitch Bloom, chair of Goodwin’s Life Sciences practice. “Scott’s vast intellectual property expertise is an invaluable addition to our one-stop shop for medtech clients navigating through a highly competitive market. We are thrilled to have Scott and his team on board as we continue to enhance our global offering at the intersection of life sciences and technology.”
Bluni counsels clients in patent-related matters such as strategic portfolio development, infringement avoidance, due diligence, enforcement, licensing, and other technology transactions. He represents medtech and other life sciences clients — from emerging startups to multibillion-dollar corporations — drawing on his experiences as a former patent examiner and chief intellectual property counsel at a large, international medtech corporation, and as a former owner and managing principal of a national intellectual property law firm.
“Goodwin’s deep bench and extensive experience in the life sciences and technology industries make it a compelling choice for medtech companies and investors,” said Bluni. “The firm’s well-integrated lifecycle platform and highly collaborative culture enable us to provide comprehensive legal and business services to clients.”
Bluni joins Goodwin’s Life Sciences practice at a time of continuous growth. In the past three years, the practice has nearly doubled its headcount to more than 225 lawyers, science advisors, and patent agents. During this time, the practice expanded globally to Cambridge, UK, Paris, Los Angeles, and Santa Monica, and added additional regulatory, corporate, licensing, and intellectual property depth in London, Hong Kong, Silicon Valley, San Francisco, Washington, D.C., New York, and Boston.
Goodwin’s recent representative life sciences work includes advising Moderna from inception through the rollout of its COVID-19 vaccine; representing AbCellera Biologics on its $555.5 million IPO, one of biotech’s largest IPOs; and representing MyoKardia on its $13.1 billion acquisition by Bristol Myers Squibb.
U.S. News – Best Lawyers' 2022 edition named Goodwin the Biotechnology Law Firm of the Year for the seventh time in the last eight years. LMG Life Sciences named Goodwin Firm of the Year in the corporate and intellectual property categories, and distinguished Goodwin as a lifecycle firm, denoting rankings.